Dr. Samuel Gandy: “Biogen Drug Could Inspire New Hope for Alzheimer's Treatments”
An experimental Alzheimer’s treatment being developed by biotechnology firm Biogen Idec BIIB +6.66% seemed to slow patients’ inexorable cognitive decline in a small, preliminary study. The result will probably lead to greater hope for a new strategy for drug companies: Treat Alzheimer’s patients early, when the disease is mild, and use brain imaging to make sure that every patient already has the amyloid plaques that help cause the disease. The data are “convincingly encouraging,” says Samuel Gandy, MD, an Alzheimer’s researcher at the Icahn School of Medicine at Mount Sinai who has been skeptical of medicines that, like BIIB037, are purported to work by clearing plaques of the protein amyloid from the brain. “I’m willing to suspend disbelief.” Learn more
Scientists Develop Novel Approach to Enhance Drug Delivery for Brain Tumors in Children
Mar 02, 2023 View All Press Releases
Researchers Identify the Role of an Alzheimer’s Disease Risk Gene in the Brain
Nov 30, 2022 View All Press Releases